SEC Form SCHEDULE 13G filed by Arvinas Inc.

$ARVN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ARVN alert in real time by email





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 68,713,098 Shares outstanding as of October 25, 2024 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on October 30, 2024). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on January 30, 2025.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
Citadel Advisors LLC
 
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:01/30/2025
 
Citadel Advisors Holdings LP
 
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:01/30/2025
 
Citadel GP LLC
 
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:01/30/2025
 
Citadel Securities LLC
 
Signature:/s/ Guy Miller
Name/Title:Guy Miller, Authorized Signatory
Date:01/30/2025
 
Citadel Securities Group LP
 
Signature:/s/ Guy Miller
Name/Title:Guy Miller, Authorized Signatory
Date:01/30/2025
 
Citadel Securities GP LLC
 
Signature:/s/ Guy Miller
Name/Title:Guy Miller, Authorized Signatory
Date:01/30/2025
 
Kenneth Griffin
 
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:01/30/2025

Comments accompanying signature:  * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
Get the next $ARVN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARVN

DatePrice TargetRatingAnalyst
12/10/2024$69.00Buy
BTIG Research
11/18/2024$55.00Overweight
Stephens
2/28/2024$95.00 → $80.00Outperform
Oppenheimer
2/14/2024$36.00 → $55.00Buy → Neutral
Citigroup
2/1/2024$70.00Buy
Goldman
12/19/2023$25.00 → $63.00Equal Weight → Overweight
Wells Fargo
12/6/2023$40.00Hold → Buy
Jefferies
11/20/2023Neutral → Buy
Guggenheim
More analyst ratings

$ARVN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Arvinas to Participate in Upcoming Investor Conferences

    NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11. Andrew Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company's website.Jefferies Biotech on the Beach Summit on Wednesday, March 12. Andrew Saik, Chief Financial

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Announced the planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025 – –

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

    NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology compan

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARVN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ARVN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARVN
SEC Filings

See more

$ARVN
Leadership Updates

Live Leadership Updates

See more
  • Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm

    $ARVN
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

    Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

    $ARVN
    $GMDA
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

    - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D. "It is a pleasure to welcome Andrew as our new Chief Financial Officer," said John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas. "Andrew is a seasoned executive in biopharma finance with extensive

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARVN
Financials

Live finance-specific insights

See more
  • Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Announced the planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025 – –

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

    NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology compan

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    – On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data for the PROTAC LRRK2 degrader ARV-102 demonstrating that LRRK2 degradation affects biomarkers in the CSF – - $1.1 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2024 - – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARVN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more